Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
Go or no go? Abbvie, Glaxo and Heron await FDA verdicts
Notable US regulatory decisions due in April feature a major pipeline hope from Abbvie, a non-opioid pain medication from Heron and Glaxo’s two-pill HIV regimen.
Ketoacidosis worries could scupper Lexicon
US approval of Lexicon and Sanofi’s SGLT inhibitor in type 1 diabetes hangs in the balance after an adcom tie.
JP Morgan 2019 day three roundup – Abbvie rekindles the takeover flame
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
Novo’s next big diabetes bet heads to regulators
Showing a cardiovascular benefit would have been icing on the cake for Novo Nordisk’s oral GLP-1 agonist, but the data still look strong enough to support blockbuster…
AHA 2018 – Astrazeneca takes heart from partial Farxiga victory
The Declare-Timi trial’s success was driven by a decrease in cardiovascular hospitalisations rather than deaths, but Astra put this down to the lower-risk population…
Political gridlock could be good for biopharma
Split congressional control will result in more drug pricing talk, but don’t expect much action.
Abbvie manoeuvres to defend Humira to the last
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.